{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:31:07Z","timestamp":1783042267866,"version":"3.54.6"},"reference-count":52,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy has prompted the development of multiple clinical trials addressing this question. This review seeks to outline and expand the current standard of care, as well as new advances, in the treatment of adult patients with ALL and address future areas of research. We expect the frontline integration of immuno-oncology agents such as bispecific T-cell engagers, antibody\u2013drug conjugates, and chimeric antigen receptor (CAR) T cells may maintain or improve outcomes in adults while also minimizing toxicity. Treatment of ALL will continue to evolve as we focus on personalized, patient-centered approaches.<\/jats:p>","DOI":"10.3390\/cells14050371","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T03:26:21Z","timestamp":1741058781000},"page":"371","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"14","author":[{"given":"Oscar","family":"Sucre","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saagar","family":"Pamulapati","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Muzammil","sequence":"additional","affiliation":[{"name":"Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8167-1928","authenticated-orcid":false,"given":"Jacob","family":"Bitran","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/10428194.2017.1335397","article-title":"Continuing challenges and current issues in acute lymphoblastic leukemia","volume":"59","author":"Kansagra","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2018-08-832105","article-title":"How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"133","author":"Ravandi","year":"2019","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/asheducation-2018.1.9","article-title":"Antibody-based therapies in patients with acute lymphoblastic leukemia","volume":"2018","author":"Dinner","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100908","DOI":"10.1016\/j.blre.2021.100908","article-title":"Optimizing use of L-asparaginase\u2013based treatment of adults with acute lymphoblastic leukemia","volume":"53","author":"Douer","year":"2022","journal-title":"Blood Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"Boissel","year":"2024","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: Long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1182\/blood-2022-157358","article-title":"The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study","volume":"140","author":"Short","year":"2022","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1182\/blood-2024-210481","article-title":"The Safety and Efficacy of Inotuzumab Treatment for Elderly Unfit r\/r B ALL","volume":"144","author":"Lin","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3324\/haematol.2023.283275","article-title":"Central nervous system therapy in acute lymphoblastic leukemia: No more, no less","volume":"108","author":"Rives","year":"2023","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/blood-2024-193954","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"144","author":"Rafaeli","year":"2024","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Raff","year":"2006","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"Zugmaier","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2020007311","article-title":"Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia","volume":"137","author":"Ribera","year":"2021","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101193","DOI":"10.1016\/j.beha.2020.101193","article-title":"Molecular markers in ALL: Clinical implications","volume":"33","author":"Kimura","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"Kneba","year":"2012","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"112972","DOI":"10.18632\/oncotarget.22934","article-title":"Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT","volume":"8","author":"Canaani","year":"2017","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","article-title":"Nelarabine: When and how to use in the treatment of T-cell acute lymphoblastic leukemia","volume":"8","author":"Shimony","year":"2024","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1182\/blood-2021-144548","article-title":"Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE\u00ae Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed\/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia","volume":"138","author":"Rizzieri","year":"2021","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bay\u00f3n-Calder\u00f3n, F., Toribio, M.L., and Gonz\u00e1lez-Garc\u00eda, S. (2020). Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207685"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: A dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: A post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","article-title":"A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Short","year":"2024","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","article-title":"Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia","volume":"9","author":"Luskin","year":"2025","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: The DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2021.279851","article-title":"Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study","volume":"107","author":"Cerrano","year":"2022","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2010-01-242750","article-title":"How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"116","author":"Fielding","year":"2010","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","volume":"386","author":"Chiaretti","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/hematology.2022000338","article-title":"Ph+ ALL in 2022: Is there an optimal approach?","volume":"2022","author":"Wieduwilt","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Salvaris, R., and Fedele, P.L. (2021). Targeted Therapy in Acute Lymphoblastic Leukaemia. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080715"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1182\/blood-2024-202558","article-title":"Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center","volume":"144","author":"Mohamed","year":"2024","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2016.11.002","article-title":"Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia","volume":"46","author":"Churchman","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: A high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: A report from the Children\u2019s Oncology Group","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3324\/haematol.2020.247973","article-title":"Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.2023023153","article-title":"How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults","volume":"145","author":"Tran","year":"2024","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1080\/10428194.2022.2090550","article-title":"Treatments of Ph-like acute lymphoblastic leukemia: A real-world retrospective analysis from a single large center in China","volume":"63","author":"Xu","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"101242","DOI":"10.1016\/j.beha.2021.101242","article-title":"Have any strategies in Ph-like ALL been shown to be effective?","volume":"34","author":"Aldoss","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/5\/371\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:46:38Z","timestamp":1760028398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/5\/371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cells14050371"],"URL":"https:\/\/doi.org\/10.3390\/cells14050371","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}